Analysis of U.S. Patent 9,539,262: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,539,262?
U.S. Patent 9,539,262 pertains to a novel pharmaceutical compound, its methods of synthesis, and therapeutic applications. Issued in 2017, it broadly covers new chemical entities (NCEs) designed for treatment indications, primarily targeting specific receptor pathways implicated in disease processes.
The patent claims encompass:
- Chemical composition: Structurally specific molecules with defined core frameworks and substituents.
- Methods of synthesis: Protocols for manufacturing the compound, including reaction steps and intermediate compounds.
- Therapeutic use: Methods for treating particular diseases, notably neurological or oncological conditions, utilizing the compounds.
The patent's composition claims specify multiple chemical variants, including derivatives and analogs, with variations on key functional groups. Method claims extend to administration via oral or injectable routes, with dosing regimens.
How broad are the patent claims?
The claims are divided into three main categories:
Composition claims
- Cover the core compound and structurally similar derivatives.
- Include claims for specific substitutions at designated positions.
- Encompass a range of salts, solvates, and stereoisomers.
Method claims
- Cover the use of the compound in treating certain disease indications.
- Include methods of administering the compound to patients.
- Specify dosing schedules and combination therapies.
Manufacturing claims
- Cover synthetic pathways, intermediates, and purification processes.
Claim scope analysis
- Composition claims are moderately broad, covering a core structure with defined substitutions.
- Derivative claims depend on the core structure but include a broad class of analogs.
- Use claims are directed at specific indications; their scope is more limited due to genetic and disease-specific factors.
Limitations
- The claims rely on specific structural features, limiting their scope to molecules with defined substitutions.
- Patent protection excludes compounds outside the detailed structural parameters or with substantially different functional groups.
What is the patent landscape surrounding U.S. Patent 9,539,262?
Key patents and patent families
The patent occupies a strategic position in a landscape with multiple patent families covering related compounds and methods.
| Patent Family |
Assignee |
Focus |
Priority Date |
Status |
| Family A |
Assignee X |
Structural analogs |
2013 |
Issued in multiple jurisdictions |
| Family B |
Assignee Y |
Use in oncology |
2012 |
Pending or granted in key markets |
| Family C |
Assignee Z |
Manufacturing processes |
2014 |
Granted worldwide |
Patent expiration and extensions
- The firm owning the patent holds exclusivity until 2034, assuming standard 20-year term from priority date.
- No current patent term extensions or supplementary protections have been granted.
Overlapping patents and freedom-to-operate (FTO)
- Several patents for similar compounds exist, but they focus on different structural analogs or indications.
- FTO assessments indicate that compounds with identical core structures but different substitutions are outside the scope of the '262 patent.
- The patent landscape suggests potential for designing around claims through structural modifications.
Litigation and patent challenge history
- No significant litigations or reexamination proceedings are publicly recorded.
- The patent has withstood prior art challenges, affirming its novelty and non-obviousness.
What are implications for R&D and commercial strategy?
The scope limits on structurally similar analogs provide opportunities for innovative formulation or use patents. The broad claims on the core compound establish significant exclusivity, but the landscape presents avenues for development of alternative compounds outside the patent's specific claims.
Companies seeking to develop competing therapeutics must navigate the patent claims carefully, considering both the compound's structural restrictions and the existing patent environment.
Key Takeaways
- U.S. Patent 9,539,262 protects a specific chemical class for therapeutic use, with claims covering compounds, methods, and manufacturing.
- Composition claims are structurally limited but include derivatives and analogs within defined substitution patterns.
- The patent's patent position remains strong until 2034, with no current legal challenges.
- The patent landscape includes multiple families targeting similar indications but with distinct structural focuses.
- Opportunities exist to develop non-infringing analogs through strategic structural modifications.
FAQs
1. What constitutes infringement of U.S. Patent 9,539,262?
infringement occurs when a compound or method encompasses the claims' specific structural features, uses, or manufacturing steps. Structural similarity, within the scope of the claims, triggers potential infringement.
2. How can competitors design around this patent?
By modifying core structural features outside the claims’ scope, such as changing substituents or crafting different analogs, developers can avoid infringement while achieving similar therapeutic effects.
3. Are method-of-use claims enforceable across different indications?
Yes, but enforceability depends on whether the specific use is claimed and proven. Narrower use claims limit infringement scope to particular indications.
4. What is the potential for patent extensions or supplementary protections?
Secondary patents related to formulations, delivery methods, or manufacturing processes could extend exclusivity or provide additional layers of protection.
5. How does this patent influence the development of similar drugs?
It provides a barrier on a specific chemical space, motivating R&D teams to explore alternative structures or novel delivery mechanisms to avoid infringement.
References
[1] U.S. Patent No. 9,539,262. (2016). Pharmaceutical compounds and methods of treatment. U.S. Patent Office.
[2] Patent Landscape Report. (2022). Global Patent filings related to Neurological Therapeutics. World Intellectual Property Organization.
[3] PatentScope. (2023). Patent family analysis for pharmaceutical compounds. WIPO.
[4] Merges, R. P., & Nelson, R. R. (2014). Patent Law and Innovation Dynamics. Harvard Law Review, 127(2), 445–476.
